Recuro Health offers a Digital Medical Home that integrates diagnostic-enabled virtual primary care, virtual behavioral health, at-home lab testing, and genomics alongside care navigation, pharmacy, and care management. The platform combines advanced science, data, at-home diagnostics and targeted genomics (including cancer screening and pharmacogenomics) to inform integrated care. Recuro positions its service as proactive and personalized, aiming to shift care from reactive, disease-focused models to preventive population health. The company plans to use new capital to advance and scale its Digital Medical Home and next-generation digital care services. Its solutions are available nationwide and are used by millions of members. Michael Gorton is CEO and founder, and the company highlights capabilities such as data analytics, quality, and guided referrals. Recuro Health operates a virtual health platform called the Digital Medical Home, providing a curated suite of digital solutions including primary care, behavioral health, at-home testing, and genetic screening. The platform is fully customizable to meet the needs of specific populations and enables patients to engage with physicians, receive personalized care, and monitor health remotely. Recuro serves payers, employers, and providers and positions itself to lower costs while improving access and outcomes as care shifts from traditional in-person settings to wherever patients and data are located. The company launched in March 2021 and is led by founder and CEO Michael Gorton. Recuro announced a convertible note financing co-led by ARCH Venture Partners and Cortado Ventures to fund its ongoing acquisition strategy and support continued growth. Cortado’s involvement marks its third investment in the company, signaling continued backer support. Recuro Health operates a customizable virtual health platform that bundles digital solutions from primary care and behavioral health to at-home testing and genetic screening. Its platform is designed to support payers, employers and providers and to create a personalized, holistic digital medical home that enables population-health and outcomes-focused care. Since launching in March 2021, Recuro has developed offerings including a widely adopted COVID-19 rapid testing solution used by employers and government customers. The company says its solutions enable earlier interventions, supplement in-person care, and provide detailed member health mosaics for risk stratification and diagnostics. Recuro plans to use the Series A proceeds to execute an acquisition strategy, expand marketing, and further build on growth since launch. Financially, Recuro announced a $15 million Series A led by ARCH Venture Partners with follow-on support from seed investors OLSF Ventures, Cortado Ventures, 1843 Capital and Sage Venture Partners. Recuro Health offers an integrated digital health platform that combines digital health tools with a patient-centered medical home, leveraging analytics and services to support patients across their entire health journeys. The company provides digital and virtual services that aggregate data to direct users to effective and efficient offerings, and evaluates outcomes and compliance to generate appropriate referrals and recommendations. Recuro says it is focused on empowering patients with tools, education and guidance to live healthier, longer and happier lives. Leadership includes Michael Gorton, founding CEO of Teladoc, alongside Teladoc's original CTO and marketing team, and additions such as Jay Sanders, MD. The company is building infrastructure and partnerships to support care delivery in every setting and to minimize the need for acute, episodic care. Recuro serves employers, providers and managed care organizations and plans to follow its current close with a larger funding round to accelerate growth.

Total raised

$62M

Funding rounds

4

Latest round

Series B

Latest activity

Apr 2023